Cart
sales@molnova.com
Emprumapimod
CAS No. 765914-60-1
Emprumapimod( —— )
Catalog No. M35693 CAS No. 765914-60-1
Emprumapimod (PF-07265803) is an orally active and specific inhibitor of mitogen-activated protein kinase p38α MAPK, inhibits LPS-induced production of IL-6, and can be used to study dilated cardiomyopathy induced by the LMNA gene.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 400 | Get Quote |
|
| 5MG | 511 | Get Quote |
|
| 10MG | 816 | Get Quote |
|
| 50MG | 1582 | Get Quote |
|
| 100MG | 2088 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameEmprumapimod
-
NoteResearch use only, not for human use.
-
Brief DescriptionEmprumapimod (PF-07265803) is an orally active and specific inhibitor of mitogen-activated protein kinase p38α MAPK, inhibits LPS-induced production of IL-6, and can be used to study dilated cardiomyopathy induced by the LMNA gene.
-
DescriptionEmprumapimod (PF-07265803) is a potent, orally active and selective inhibitor of p38α MAPK directly inhibits LPS-induced IL-6 production from RPMI-8226 cell (IC50=100 pM). Emprumapimod can be used for the research of dilated cardiomyopathy and acute inflammatory pain.
-
In Vitro——
-
In VivoAnimal Model:LmnaH222P/H222P mice were Dosage:30 mg/kg Administration:Administered orally by gavage starting when mice were 16 weeks of age and continuing until 20 weeks of age Result:There were significant increases in LVEDD and LVESD as well as a decrease in FS, a parameter directly proportional to the LV ejection fraction.
-
Synonyms——
-
PathwayMAPK/ERK Signaling
-
Targetp38 MAPK
-
Recptorp38 MAPK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number765914-60-1
-
Formula Weight473.52
-
Molecular FormulaC24H29F2N5O3
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (211.18 mM; Ultrasonic )
-
SMILESC(C(C)C)N1C=2C(=CC(OC3=C(F)C=C(F)C=C3)=C(C(N[C@@H](CCN(C)C)C(N)=O)=O)C2)C=N1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Dale Wright, et al. ARRY-797, a Potent and Selective Inhibitor of p38 Map Kinase, Inhibits LPS-Induced IL-6 and In Vivo Growth of RPMI-8226 Human Multiple Myeloma Cells.
molnova catalog
related products
-
SR-318
SR-318 potently inhibits the TNF-α release in whole blood (IC50 = 283 nM). SR-318 is a potent and highly selective inhibitor of p38 MAPK. The IC50 values are 5 nM, 32 nM and 6.11 μM for p38α, p38β and p38α/β, respectively.
-
Pardoprunox hydrochl...
Pardoprunox hydrochloride is a novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist.
-
NJK14047
NJK14047 is a novel potent, selective p38 MAPK inhibitor with IC50 of 27 nM against p38α.
